经颈静脉肝穿刺活检在疑难重症肝病诊治中的应用

田华; 余强; 游绍莉; 吕飒; 刘树红; 朱冰

doi:10.3969/j.issn.1001-5256.2021.12.027

经颈静脉肝穿刺活检在疑难重症肝病诊治中的应用

DOI: 10.3969/j.issn.1001-5256.2021.12.027

田华^a,
余强^b,
游绍莉^a,
吕飒^a,
刘树红^c,
朱冰^a, ,

a.
解放军总医院第五医学中心肝病医学部肝病科，北京 100039
b.
解放军总医院第五医学中心肿瘤医学部介入科，北京 100039
c.
解放军总医院第五医学中心病理科，北京 100039

基金项目:

首都特色重点课题 (Z151100004015019)

详细信息

通信作者:
朱冰，zhubing302@163.com

中图分类号: R575
计量
- 文章访问数: 426
- HTML全文浏览量: 105
- PDF下载量: 48
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-24
- 录用日期: 2021-07-05
- 出版日期: 2021-12-20

Application of transjugular liver biopsy in the diagnosis and treatment of complicated and severe liver diseases

a.
Department of Liver Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
b.
Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
c.
Department of Pathology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

Research funding:

Capital Clinical Characteristic Application Research on Funded Projects (Z151100004015019)

摘要

摘要: 目的探讨经颈静脉肝穿刺活检(TJLB)在疑难重症肝病诊断及治疗中应用的意义。方法回顾性分析2016年1月-2021年5月在解放军总医院第五医学中心接受TJLB的31例患者的临床资料，对穿刺的适应证、成功率、最终诊断结果进行分析。结果 31例患者中男15例，女16例。8例因肝衰竭凝血机制障碍、13例因肝硬化合并腹水、10例因肝硬化合并血小板减少(＜50×10⁹/L)不宜行经皮肝穿刺活检，符合实施TJLB适应证。TJLB穿刺成功率100%，穿刺条数2~4条。无严重不良事件。患者出院明确诊断26例(83.87%)。其中特发性门静脉高压5例，药物性肝衰竭或肝硬化9例，自身免疫性肝病5例，其他原因肝硬化或肝衰竭7例，尚不能明确病因者5例，此外，为证实诊断及决策是否肝移植患者3例。结论 TJLB在疑难重症肝病诊治中发挥重要作用，但尚有一定局限性，临床上应注意筛选适宜患者实施。
- 肝疾病 /
- 活组织检查, 针吸 /
- 诊断 /
- 治疗学
Abstract: Objective To investigate the application value of transjugular liver biopsy (TJLB) in the diagnosis and treatment of complicated and severe liver diseases. Methods A retrospective analysis was performed for the clinical data of 31 patients who underwent TJLB in The Fifth Medical Center of Chinese PLA General Hospital, including indication for puncture, success rate, and final diagnosis. Results Among the 31 patients, there were 15 male patients and 16 female patients. Percutaneous liver biopsy was unsuitable for 8 patients with liver failure and disturbances of blood coagulation, 13 with liver cirrhosis and ascites, and 10 with liver cirrhosis and thrombocytopenia (< 50×10⁹/L), which were the indications for TJLB. The success rate of TJLB puncture was 100%, with 2-4 passes for puncture. No serious adverse event was observed. Of all 31 patients, 26 (83.87%) had a definite diagnosis at discharge, among whom there were 5 patients with idiopathic portal hypertension, 9 patients with drug-induced liver failure or liver cirrhosis, 5 patients with autoimmune liver disease, and 7 patients with liver cirrhosis or liver failure due to other causes, and 5 patients had unknown etiology. In addition, 3 patients underwent biopsy to confirm the diagnosis and decision of whether liver transplantation should be performed. Conclusion TJLB plays an important role in the diagnosis and treatment of complicated and severe liver diseases and still has certain limitations, and therefore, suitable patients should be selected in clinical practice.
- Liver Diseases /
- Biopsy, Needle /
- Diagnosis /
- Therapeutics

HTML全文

图 1 部分患者肝活检病理结果

注: a，汇管区内门静脉壁厚，部分肝窦轻度扩张，未见肝硬化表现(HE染色，×200);b，肝硬化，Laennec分期F4C(HE染色，×100);c，假小叶形成(肝硬化)，明显的融合状坏死和桥接坏死，大量的炎性细胞浸润，界面炎明显(HE染色，×10);d，肝窦充满均质粉染物，肝细胞萎缩消失，偏振光下呈苹果绿折光性(右上，刚果红)(HE染色，×400);e，汇管区中度混合性炎细胞浸润，固有胆管尚存，周边细胆管反应增生，有的细胆管扩张含胆栓(HE染色，×200);f，亚急性肝炎，重度肝内淤胆，肝细胞及毛细胆管淤胆易见(HE染色，×10)。

下载: 全尺寸图片幻灯片

表 1 患者相关化验指标

指标	数值
Alb(g/L)	33.00(28.00~37.00)
ALT(U/L)	33.00(18.00~63.00)
AST(U/L)	49.00(35.00~140.00)
ALP(U/L)	149.00(84.00~266.00)
GGT(U/L)	98.00(27.00~156.00)
TBil(μmol/L)	57.30(18.10~164.60)
PTA(%)	52.90(42.90~70.60)
INR	1.37(1.13~1.58)
WBC(×10⁹/L)	3.38(2.14~5.30)
Hb(g/L)	105.00(93.00~124.00)
PLT(×10⁹/L)	68.00(47.00~118.00)
注：数据描述方式为M (P₂₅~P₇₅)。

下载: 导出CSV

参考文献(17)

[1]	BRAVO AA, SHETH SG, CHOPRA S. Liver biopsy[J]. N Engl J Med, 2001, 344(7): 495-500. DOI: 10.1056/NEJM200102153440706.
[2]	DOHAN A, GUERRACHE Y, BOUDIAF M, et al. Transjugular liver biopsy: Indications, technique and results[J]. Diagn Interv Imaging, 2014, 95(1): 11-15. DOI: 10.1016/j.diii.2013.08.009.
[3]	CADRANEL JF, NOUSBAUM JB, GOUILLOU M, et al. Major changes in the number and indications of liver biopsy for chronic liver diseases over one decade in France[J]. Eur J Gastroenterol Hepatol, 2016, 28(9): e26-e32. DOI: 10.1097/MEG.0000000000000683.
[4]	LYU S, YOU SL, YU Q, et al. Feasibility and significance of transjugular liver biopsy in diagnosis and treatment of complicated and severe liver diseases: A single-center analysis of 5 cases[J]. Chin J Hepatol, 2017, 25(10): 772-774. DOI: 10.3760/cma.j.issn.1007-3418.2017.10.011. 吕飒, 游绍莉, 余强, 等. 经颈静脉肝穿刺活组织检查在疑难重症肝病诊治中的可行性及意义: 单中心5例患者分析[J]. 中华肝脏病杂志, 2017, 25(10): 772-774. DOI: 10.3760/cma.j.issn.1007-3418.2017.10.011.
[5]	CRAWFORD AR, LIN XZ, CRAWFORD JM. The normal adult human liver biopsy: A quantitative reference standard[J]. Hepatology, 1998, 28(2): 323-331. DOI: 10.1002/hep.510280206.
[6]	YOU SL, ZHU B, RONG YH, et al. Diagnosis analysis of 9453 cases with liver diseases[J]. Chin J Health Care Med, 2012, 14(6): 459-462. DOI: 10.3969/j.issn.1674-3245.2012.06.017. 游绍莉, 朱冰, 荣义辉, 等. 9453例待查肝病的诊断分析[J]. 中华保健医学杂志, 2012, 14(6): 459-462. DOI: 10.3969/j.issn.1674-3245.2012.06.017.
[7]	BERNAL W, WENDON J. Acute liver failure[J]. N Engl J Med, 2013, 369(26): 2525-2534. DOI: 10.1056/NEJMra1208937.
[8]	YOU S, RONG Y, ZHU B, et al. Changing etiology of liver failure in 3, 916 patients from northern China: A 10-year survey[J]. Hepatol Int, 2013, 7(2): 714-720. DOI: 10.1007/s12072-013-9424-5.
[9]	European Association for the Study of the Liver. EASL clinical practice guidelines: Vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
[10]	KHANNA R, SARIN SK. Non-cirrhotic portal hypertension-diagnosis and management[J]. J Hepatol, 2014, 60(2): 421-441. DOI: 10.1016/j.jhep.2013.08.013.
[11]	REN Y, ZHENG SJ. Progress of idiopathic portal hypertension[J]. Chin J Gastroenterol Hepatol, 2019, 28(6): 708-710. DOI: 10.3969/j.issn.1006-5709.2019.06.025. 任艳, 郑素军. 特发性门脉高压研究现状[J]. 胃肠病学和肝病学杂志, 2019, 28(6): 708-710. DOI: 10.3969/j.issn.1006-5709.2019.06.025.
[12]	MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
[13]	ZHAO LH, JIA JD. Etiological diagnosis and standard treatment of portal hypertension should be taken seriously[J]. J Clin Hepatol, 2019, 35(1): 10-12. DOI: 10.3969/j.issn.1001-5256.2019.01.001. 赵连晖, 贾继东. 应重视门静脉高压症的病因诊断及规范治疗[J]. 临床肝胆病杂志, 2019, 35(1): 10-12. DOI: 10.3969/j.issn.1001-5256.2019.01.001.
[14]	Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS), Minimally Invasive Intervention Collaborative Group, Chinese Society of Gastroenterology, Emergency Intervention Committee, Chinese College of Interventionalists, et al. Consensus on clinical application of hepatic venous pressure gradient in China (2018)[J]. J Clin Hepatol, 2018, 34(12): 2526-2536. DOI: 10.3969/j.issn.1001-5256.2018.12.008. 中国门静脉高压诊断与监测研究组(CHESS), 中华医学会消化病学分会微创介入协作组, 中国医师协会介入医师分会急诊介入专业委员会, 等. 中国肝静脉压力梯度临床应用专家共识(2018版)[J]. 临床肝胆病杂志, 2018, 34(12): 2526-2536. DOI: 10.3969/j.issn.1001-5256.2018.12.008.
[15]	ROCKEY DC, CALDWELL SH, GOODMAN ZD, et al. Liver biopsy[J]. Hepatology, 2009, 49(3): 1017-1044. DOI: 10.1002/hep.22742.
[16]	BEHRENS G, FERRAL H. Transjugular liver biopsy[J]. Semin Intervent Radiol, 2012, 29(2): 111-117. DOI: 10.1055/s-0032-1312572.
[17]	BEHRENS G, FERRAL H, GIUSTO D, et al. Transjugular liver biopsy: Comparison of sample adequacy with the use of two automated needle systems[J]. J Vasc Interv Radiol, 2011, 22(3): 341-345. DOI: 10.1016/j.jvir.2010.10.012.